Evidence map›Paper›PMID 40171815›Full record

ArticleCancer biomarkers : section A of Disease markers2025

Development and validation of machine learning models for early diagnosis and prognosis of lung adenocarcinoma using miRNA expression profiles.

Lin Lin, Yongxia Bao

Abstract read
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lin LinDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
Yongxia BaoDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ObjectiveStudy aims to develop diagnostic and prognostic models for lung adenocarcinoma (LUAD) using Machine learning(ML)algorithms, aiming to enhance clinical decision-making accuracy.MethodsData from The Cancer Genome Atlas (TCGA) for LUAD patients were split into training (n = 196) and test sets (n = 133). Feature selection (Least Absolute Shrinkage and Selection Operator (LASSO), Random Forest (RF), and Support Vector Machine (SVM)) identified miRNAs distinguishing stage I LUAD. Six ML algorithms predicted pulmonary node classification. Model performance was evaluated using Receiver Operating Characteristic (ROC) curve, Precision-Recall (PR) curves, and Error Rates (CE). A prognostic model was constructed using Lasso Cox regression. Risk score plots were generated, and model performance was assessed using Kaplan-Meier (K-M) and time-dependent ROC curves. Functional enrichment analyses investigated miRNA function and mechanism.ResultsThe feature selection results identified five miRNA molecules as distinguishing characteristics between early-stage LUAD and adjacent non-cancerous tissues. A prognostic model using 13 miRNAs predicted poorer outcomes for patients with higher risk scores, supported by time-dependent ROC curves and a nomogram. Functional enrichment analysis identified cancer-related signaling pathways for the biomarkers.ConclusionML identified a diagnostic five-miRNA signature and a prognostic 13-miRNA model for LUAD, both robust and reliable.

Indexed as

Adenocarcinoma of LungBiomarkers, TumorEarly Detection of CancerLung NeoplasmsMachine LearningMicroRNAsAgedFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisROC CurveBiomarkers, TumorMicroRNAslung adenocarcinomamachine learningmiRNAprognostic model

Identifiers

PMID40171815
PMCPMC12288384

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.